Sepp-Lorenzino Laura
EVP, Chief Scientific Officer at NTLA
- Sold, on record
- $19.3M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Jan 3, 2025
- Form 144 notices
- 1
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- NTLAIntellia Therapeutics, Inc.EVP, Chief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale NTLAUnusualAug 4, 2021 2021
Sold 26,000 shares at $138.24 ($3.6M)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
Sold 91.6% of holdings ($3.9M position)2,391 shares leftFirst sale on recordFiling
- 2 Form 4 sale NTLAUnusualAug 30, 2021 +26 days
Sold 97,000 shares at $154.83 ($15M)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
Sold 97.6% of holdings ($15.4M position)2,391 shares leftFiling
- 3 Form 4 sale NTLAPlan not statedJan 1, 2022 +124 days
Sold 1,148 shares at $112.25 ($129k)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
Sold 19.3% of holdings ($669k position)4,815 shares leftFiling
- 4 Form 4 sale NTLAPlan not statedJan 5, 2023 +369 days
Sold 4,838 shares at $37.82 ($183k)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
Sold 21.5% of holdings ($850k position)17,629 shares left0.2x usual sizeFiling
- 5 Form 4 sale NTLANo planJan 3, 2024 +363 days
Sold 5,532 shares at $29.46 ($163k)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
No 10b5-1 planSold 10.7% of holdings ($1.5M position)46,202 shares leftFiling
- 6 Form 144 notice NTLANoticeJan 8, 2024 +5 days
Filed to sell 2,275 shares ($64k)
Sepp-Lorenzino Laura, Officer
10b5-1 planFiling
- 7 Form 4 sale NTLARoutineJan 8, 2024 same day
Sold 2,275 shares at $28.87 ($66k)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
10b5-1 planSold 4.9% of holdings ($1.3M position)43,927 shares leftFollows a Form 144Filing
- 8 Form 4 sale NTLANo planJan 3, 2025 +361 days
Sold 8,966 shares at $12.18 ($109k)
Sepp-Lorenzino Laura, EVP, Chief Scientific Officer
No 10b5-1 planSold 10.4% of holdings ($1.1M position)77,388 shares left1.9x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (8)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | Jan 7, 2025 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 8,966 | $109k | 10.4% | No plan | SEC |
| Jan 8, 2024 | Jan 10, 2024 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 2,275 | $66k | 4.9% | Routine | SEC |
| Jan 8, 2024 | Jan 8, 2024 | NTLA | Officer | Form 144 notice | 2,275 | $64k | Notice | SEC | |
| Jan 3, 2024 | Jan 5, 2024 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 5,532 | $163k | 10.7% | No plan | SEC |
| Jan 5, 2023 | Jan 6, 2023 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 4,838 | $183k | 21.5% | Plan not stated | SEC |
| Jan 1, 2022 | Mar 3, 2022 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 1,148 | $129k | 19.3% | Plan not stated | SEC |
| Aug 30, 2021 | Sep 1, 2021 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 97,000 | $15M | 97.6% | Unusual | SEC |
| Aug 4, 2021 | Aug 6, 2021 | NTLA | EVP, Chief Scientific Officer | Form 4 sale | 26,000 | $3.6M | 91.6% | Unusual | SEC |